[Featured Stock] BioLeaders Rises Amid Spread of COVID-19 Delta Variant

[Asia Economy Reporter Jang Hyowon] BioLeaders is showing strength as the quarantine authorities mentioned the need to strengthen management due to the domestic spread of the COVID-19 Delta variant.

As of 10:45 AM on the 1st, BioLeaders is trading at 7,780 KRW, up 4.85% compared to the previous trading day.

The rapid increase in domestic Delta variant infections has drawn attention to BioLeaders, which is developing variant COVID-19 treatments and vaccines.

According to the government on this day, domestic Delta variant infections have exceeded 500. Adding 213 cases related to native English instructors at an English academy in the Gyeonggi region, the number of Delta variant infections is already approaching 572. The government has made a sudden decision to postpone the implementation of new 'social distancing' measures in Seoul and the metropolitan area by one week.

Additionally, the Central Disease Control Headquarters stated at the regular briefing on the 21st that regarding the 'Delta variant' originating from India, "We are continuously monitoring the situation closely and it is necessary to strengthen management."

The Delta variant is known to be the most transmissible among COVID-19 variants. In the UK, where the vaccination rate exceeds 60% of the total population, daily confirmed cases of the Delta variant have reached 20,000, and there are forecasts that the Delta variant will become the dominant strain in the United States as well.

Meanwhile, BioLeaders recently announced that it is conducting joint research with the Korea Mouse Phenotyping Consortium (KMPC) for the rapid development of oral COVID-19 treatments including variants, and plans to start Phase 2 clinical trials immediately after the upcoming second efficacy evaluation test.

It is also known that BioLeaders has begun production of the COVID-19 vaccine 'BLS-A01', which is expected to have superior efficacy and longer antibody duration against variant viruses compared to existing vaccines, through a GMP production contract with SeedMogen.